Pre-made Glofitamab biosimilar (Bispecific mAb with Domain Crossover, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Glofitamab biosimilar (Bispecific mAb with Domain Crossover, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody |
|---|---|
| INN Name | Glofitamab |
| Target | CD3E,MS4A1 |
| Format | Bispecific mAb with Domain Crossover |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None;3pp3:HL/3pp4:HL |
| 99% SI Structure | None;6y9a:HL |
| 95-98% SI Structure | None;6y97:HL |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Roche |
| Conditions Approved | NA |
| Conditions Active | Diffuse large B cell lymphoma,Follicular lymphoma,Non-Hodgkin's lymphoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD3E,MS4A1 |
| Package |
